40+ Pathogens 

Covering almost 100% more target Pathogens comparing to other Market Players

Co-designed by EVDL researchers and renowned Microbiologist Professor Kwok-Yung Yuen, our respiratory disease panel currently covers 40+ pathogens most commonly found in Asian countries, including the latest coronavirus SARS-CoV-2 (commonly known as Covid-19). This panel can detect and identify viruses, bacteria and fungi simultaneously in a single test with minimal interference. Almost doubling the number of target pathogens comparing to other market players, we believe our novel diagnostic system offers the most comprehensive coverage in the world.

Up to 50% Lower Cost

At a Lowest possible Price Point that supports wide Market Adoption

A solution to unmet medical need will benefit the healthcare sector only if it can be offered at a price point that is widely and easily accepted by the market – this is why cost is one of our major considerations at the early research and development stage. Having covered almost 100% more pathogens and at a cost of up to 50% lower than other market players, we trust this is how we differentiate ourselves and what the market welcomes.

100% PPV and 97.5% NPV*

Exceptional Sensitivity and Specificity alongside outstanding Multiplexing Capability

While Sensitivity is vital in early detection of a potentially infected individual during the onset of infection when the viral load is usually low, Specificity is critical in determining whether particular pathogen targets are present or absent in the sample. The larger the number of pathogens involved in a single test, the more difficult it is to achieve excellence in both Sensitivity and Specificity. By testing 40+ pathogens in one test with high Sensitivity and Specificity, we are definitely bringing multiplexing to the next level!

*Data on file

Medical & Non-Medical Applications

Unlimited Potential of our Diagnostic System as Platform Technology

We have always set a goal to maximize the potential of our inventions. The respiratory disease panel is only our first step. Extended coverage for other medical areas such as cancers and paediatric, as well as non medical areas like food safety and environmental testing is underway. Further pushing ourselves beyond the boundaries.

Strong IP Portfolio 

Strong Intellectual Property Portfolio as our important Asset and a way for Value Creation

As a high-tech and R&D company, protecting our know-how and innovations is of utmost importance. We possess a strong intellectual property portfolio and this creates a solid base for our future development as well as asset protection.